Chinese state firm Sinopharm aims to produce 1 billion vaccine doses in 2021 2 minutes read
By Javier Garcia
Beijing, Feb 26 (efe-epa).- The head of China’s state-owned pharmaceutical company Sinopharm, Liu Jingzhen, announced Friday that they plan to produce one billion doses of its inactivated coronavirus vaccine this year, a large part of it for export.
During a visit organized for the media to the Sinopharm facilities near Beijing, Liu revealed that the pharmaceutical company was improving its production capabilities to produce more vaccines.
Annual production of Sinopharm would account for half of the two nillion doses that China plans to produce this year, according to the National Vaccine Industry Association head Feng Duojia, who recently said that the country would double that amount by 2022.
China s CanSino files for authorization to market Covid-19 vaccine laprensalatina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from laprensalatina.com Daily Mail and Mail on Sunday newspapers.
CanSino Biologics Inc (CanSinoBIO) said China s drug regulator, the National Medical Products Administration, accepted its COVID-19 vaccine application on Wednesday.
The single-dose vaccine, developed by CanSinoBIO and a team led by Chen Wei, a researcher from the Beijing-based Academy of Military Medical Sciences, will become the country s third locally developed shot allowed for conditional use by the general public if approved.
On Chinese New Year s Eve, Gou Jinbo, who was spearheading the Chinese scientific team in Pakistan for the COVID-19 vaccine Phase III clinical trials, scoffed up a few dumplings and rushed back to the clinical trial site.
The COVID-19 vaccine candidate manufactured by Chinese firm CanSino Biologics has an overall efficacy rate of 65.7 percent at preventing symptomatic cases and is 90.98 percent effective in preventing severe disease with a single injection, according to multinational interim analysis of the vaccine s late-stage human trials.
Experts called the results encouraging because the vaccine is one of the few requiring a single shot, is easy to store and is generally safe, even for the elderly. Having a potent one-shot vaccine also means more countries can carry out a wider, more affordable rollout strategy compared with those that require two shots and deep-freezing logistics, they added.